| Document |
Document Title |
|
WO/2013/188381A1 |
The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A2, A3, A4, J, and X 3have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof...
|
|
WO/2013/174075A1 |
Provided in the present invention are an iridium complex containing functional groups for hole transporting and an electroluminescent device thereof. The complex is a metal iridium complex having three identical ligands, wherein a new li...
|
|
WO/2013/152359A1 |
Provided herein, inter alia, are compositions and methods of synthesis and detection of tetrazines and diazonorcaradienes.
|
|
WO/2013/149977A1 |
This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula I wherein B1 to B3 and R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. The...
|
|
WO/2013/140969A1 |
The present invention is a photoresist composition which contains [A] a polymer that has a structural unit (I) containing an acid-cleavable group and a compound (I) that is represented by formula (1). In formula (1), each of R1, R2, R3 a...
|
|
WO/2013/131935A1 |
The present invention relates to compounds of general formula I, wherein the groups R1, R2, L1, L2, U and B are as defined in the application, which have valuable pharmacological properties, and in particular modulate the activity of the...
|
|
WO/2013/129622A1 |
The present invention provides a compound having cholinergic muscarinic M1 receptor positive allosteric modulator activity, that is useful as a drug for preventing or treating Alzheimer's disease, schizophrenia, pain, sleep disorders, an...
|
|
WO/2013/126856A1 |
In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6- carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine rec...
|
|
WO/2013/107336A1 |
This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis.
|
|
WO/2013/104573A1 |
The present invention relates to the use of novel triazolopyridine derivatives of formula (I): wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune an...
|
|
WO/2013/102826A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...
|
|
WO/2013/100027A1 |
Provided is a heterocyclic compound having RORγt-inhibiting activity. A compound represented by formula (1) (in the formula, each substituent is as stated in the specification) or a salt thereof.
|
|
WO/2013/090497A1 |
Pyridazinone compounds of Formula I: (I) wherein: R' is alkyl or Ar, optionally substituted with at least one alkyl, halo¬ gen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, a...
|
|
WO/2013/087743A1 |
The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in ...
|
|
WO/2013/083774A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a c...
|
|
WO/2013/078123A1 |
The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases us...
|
|
WO/2013/072265A1 |
This invention relates to 1-pyridazinyl-hydroxyimino-3-phenyl-propanes of the formula (I) wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPB...
|
|
WO/2013/072825A1 |
The present patent application is directed to bicyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enz...
|
|
WO/2013/073577A1 |
[Problem] To provide a compound which has a D-amino acid oxidase (DAAO) inhibitory effect and is useful, for example, as a prophylactic and/or therapeutic agent for schizophrenia and neuropathic pain. [Solution] The inventors have achiev...
|
|
WO/2013/068489A1 |
Novel inhibitor compounds of phosphodiesterase type 10A The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for tr...
|
|
WO/2013/064518A1 |
A compound of formula (I), wherein R1 to R4 are, for example, each hydrogen, R5 is, for example, an unsubstituted aromatic 6-membered heterocycle; R6 is, for example,hydrogen; R7 is,for example, hydrogen, cyano, hydroxyl, formyl, C1-C4-a...
|
|
WO/2013/061297A1 |
The invention provides compounds of formula I, (I) wherein: R represents a cyclic group selected from phenyl, heteroaryl,heterocyclyl and C 3-6 cycloalkyl;10 wherein each cyclic group is optionally substituted with from 1 to 3 substituen...
|
|
WO/2013/059433A2 |
Disclosed are hybrid compounds that release both nitric oxide and a moiety that inhibits poly (ADP-ribose) polymerase (PARP), e.g., a compound or a pharmaceutically acceptable salt thereof of formula (I), wherein R1-4 and m-p are as desc...
|
|
WO/2013/054302A1 |
The invention relates to a method for preparing a derivative of formula (I): (A)3-Bi, where the A groups, identical or different, are an aryl or heteroaryl radical, optionally substituted by at least one FG group, which can occupy any po...
|
|
WO/2013/050460A1 |
The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH; with the proviso that Y can only be CH, if at least on of U, V or W are N; U is N or C-R4; V and W are independently N or CH; with the proviso that o...
|
|
WO/2013/050421A1 |
The present invention provides a compound of Formula (I) or an agronomically acceptable salt thereof, wherein:R2 is selected from the group consisting of (A1), (A2) and (A3) wherein X1 is N or CR7 X2 is N or CR8 X3 is N or CR9 X4 is N or...
|
|
WO/2013/037753A1 |
The present invention relates to novel non-steroidal brassinosteroid mimetic derivatives, to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controll...
|
|
WO/2013/035827A1 |
The purpose of the present invention is to provide: a novel compound which is represented by formula (I') and has ACC2 inhibitory activity; and a medicinal composition which contains the compound. (In the formula, R1 represents a substit...
|
|
WO/2013/030205A1 |
The present application disclosed compounds of Formula I wherein variables R1 and R2 are defined as described herein, which are inhibitors of PARP and provides compounds and compositions containing the compounds of Formula I. The present...
|
|
WO/2013/029338A1 |
Disclosed are novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/027660A1 |
A novel pesticide is provided. The present invention provides a compound represented by the formula (I) or its salt: wherein Q is phenyl or pyridyl which may be substituted; W is an oxygen atom or S(O)m; each of A1 to A5 is -C(R5)= or a ...
|
|
WO/2013/027000A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them an...
|
|
WO/2013/019938A1 |
Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2013/005157A1 |
Provided herein is novel compound of the general formula (I), its tautomeric forms, its stereoisomers, its analogs, its prodrugs, its isotopes, its N- oxides, its metabolites, its pharmaceutically acceptable salts, its polymorphs, its so...
|
|
WO/2012/173983A1 |
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
|
|
WO/2012/165648A1 |
The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH2, O, S...
|
|
WO/2012/162254A1 |
The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the ...
|
|
WO/2012/158200A1 |
Provided is a macromolecule comprising two or more functionalized bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the functionalized bis-peptides are covalently attached to one or more f...
|
|
WO/2012/155199A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
WO/2012/158399A1 |
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such ...
|
|
WO/2012/154760A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2012/141604A1 |
The invention relates to the new, asymmetrically substituted derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione and their use as cytostatics exhibiting activity against tumor cells, especially against cells with multidrug res...
|
|
WO/2012/136703A1 |
The present invention relates to novel herbicidal compounds of Formula (I), or an agronomically acceptable salt of said compound wherein R1, R2, A1, Ra, Rb, Rc and Rd are as defined herein. The invention further relates to compositions w...
|
|
WO/2012/130137A1 |
The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The present invention also discloses the use of th...
|
|
WO/2012/126570A1 |
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...
|
|
WO/2012/124696A1 |
[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result...
|
|
WO/2012/120195A1 |
The invention relates to pyridazinone and pyridone com- pounds having formula (I) or (I'), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1 / R4 and X and X3 are as defined in the claims. The invention...
|
|
WO/2012/120398A1 |
The invention provides a compound of the formula (I): wherein A, R1, R2 and R3 are as defined herein, or a pharmaceutically acceptable salt thereof. Such compounds are small molecule TRPM8 blockers and therefore useful in the propylaxis ...
|
|
WO/2012/119045A2 |
Hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, compositions comprising hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, and methods for u...
|
|
WO/2012/097682A1 |
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compoun...
|
